Cullgen Inc. is a San Diego based biotechnology company developing small molecule therapeutics based on our proprietary targeted protein degradation (TPD) technology, uSMITE™. Our TPD technology is a type of precision medicine that has the potential to address a broad range of intracellular disease targets, such as oncology, inflammation, CNS, and other diseases that cannot be addressed by existing therapies, commonly referred to as “undruggable” targets. We are currently developing a number of TPD based therapeutics in-house, primarily for oncology, that are available for co-development or licensure. Our most advanced candidate, CG001419, recently entered pre-clinical studies.

In addition to our internal pipeline of TPD programs, we are also discovering and developing novel E3 ligands in order to enhance the overall robustness and effectiveness of TPD therapeutics.